eFFECTOR Therapeutics has started dosing patients in the Phase ll expansion portion of its ongoing Phase l/ll study of eFT508 for the treatment of relapsed, refractory, non-germinal centre B cell (non-GCB) diffuse large B-cell lymphoma (DLBCL).
In this portion, patients will be given a 200mg dose of eFT508 twice daily, which was established in the Phase l dose-escalation portion of the trial.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Phase l/ll trial is an open-label, sequential-group, dose-escalation and cohort-expansion study designed to analyse the safety, pharmacokinetics, pharmacodynamics and anti-tumour activity of eFT508 in patients with haematological malignancies.
The primary objective of the expansion cohort is the objective response rate (ORR) of eFT508 in non-GCB DLBCL patients.
eFFECTOR Therapeutics president and CEO Steve Worland said: “This Phase ll expansion cohort builds on our Phase l results, where we observed a confirmed partial response in one of two non-GCB DLBCL patients enrolled during dose escalation.
“Patients with non-GCB DLBCL who have failed other available treatment options face a devastating disease.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataNon-GCB DLBCL is an aggressive form of non-Hodgkin’s lymphoma (NHL) that is partly caused by the activation of nuclear factor kappa-light-chain-enhancer of activated B-cells (NFkB) and frequently responds poorly to standard treatments.
According to the Lymphoma Research Foundation, DLBCL is estimated to account for 30% of the newly diagnosed NHL cases each year.
eFT508, an oral, small molecule inhibitor of MNK1/2, has previously secured orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of DLBCL.
